Is PSTV or SURG more profitable?

SurgePays has a net margin of -64.91% compared to Plus Therapeutics' net margin of -230.24%. SurgePays' return on equity of 0.00% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% SurgePays -64.91% N/A -310.16%

Does the media refer more to PSTV or SURG?

In the previous week, Plus Therapeutics and Plus Therapeutics both had 2 articles in the media. SurgePays' average media sentiment score of 1.29 beat Plus Therapeutics' score of 0.62 indicating that SurgePays is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SurgePays 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SURG or PETV?

SurgePays presently has a consensus price target of $3.50, suggesting a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher possible upside, research analysts plainly believe SurgePays is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, SURG or PETV?

PetVivo has lower revenue, but higher earnings than SurgePays. PetVivo is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.14 -$36.07M -$1.94 N/A PetVivo $1.05M 27.62 -$10.95M -$0.38 N/A

Is SURG or PETV more profitable?

SurgePays has a net margin of -64.91% compared to PetVivo's net margin of -902.82%. SurgePays' return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% PetVivo -902.82% -4,813.07% -281.78%

Does the media refer more to SURG or PETV?

In the previous week, SurgePays and SurgePays both had 2 articles in the media. SurgePays' average media sentiment score of 1.29 beat PetVivo's score of 0.00 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SURG or CTSO more profitable?

Cytosorbents has a net margin of -31.85% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Cytosorbents -31.85% -235.57% -37.88%

Do analysts prefer SURG or POAI?

SurgePays presently has a consensus target price of $3.50, suggesting a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher possible upside, equities analysts plainly believe SurgePays is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SURG or MODD?

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Modular Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SURG or MODD more profitable?

Modular Medical has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Modular Medical's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Modular Medical N/A -286.34% -216.26%

SurgePays (SURG) Competitors

$0.31 -0.01 (-3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$0.31 -0.01 (-2.27%)

As of 07:55 PM Eastern

Compare

SURG vs. PSTV, PETV, CTSO, POAI, and MODD

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include Plus Therapeutics (PSTV), PetVivo (PETV), Cytosorbents (CTSO), Predictive Oncology (POAI), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry.

How does SurgePays compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

In the previous week, Plus Therapeutics and Plus Therapeutics both had 2 articles in the media. SurgePays' average media sentiment score of 1.29 beat Plus Therapeutics' score of 0.62 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SurgePays	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Plus Therapeutics has higher earnings, but lower revenue than SurgePays. Plus Therapeutics is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	4.94	-$22.39M	-$2.30	N/A
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,408.02%. SurgePays has a consensus price target of $3.50, suggesting a potential upside of 1,017.85%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than SurgePays.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

SurgePays has a net margin of -64.91% compared to Plus Therapeutics' net margin of -230.24%. SurgePays' return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
SurgePays	-64.91%	N/A	-310.16%

Summary

SurgePays beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does SurgePays compare to PetVivo?

SurgePays (NASDAQ:SURG) and PetVivo (NASDAQ:PETV) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

6.9% of SurgePays shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 29.1% of SurgePays shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PetVivo has lower revenue, but higher earnings than SurgePays. PetVivo is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
PetVivo	$1.05M	27.62	-$10.95M	-$0.38	N/A

In the previous week, SurgePays and SurgePays both had 2 articles in the media. SurgePays' average media sentiment score of 1.29 beat PetVivo's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SurgePays has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

SurgePays has a net margin of -64.91% compared to PetVivo's net margin of -902.82%. SurgePays' return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
PetVivo	-902.82%	-4,813.07%	-281.78%

SurgePays presently has a consensus price target of $3.50, suggesting a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher possible upside, research analysts plainly believe SurgePays is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

SurgePays beats PetVivo on 9 of the 15 factors compared between the two stocks.

How does SurgePays compare to Cytosorbents?

SurgePays (NASDAQ:SURG) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Cytosorbents has lower revenue, but higher earnings than SurgePays. Cytosorbents is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 7.8% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,017.85%. Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than SurgePays.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has a net margin of -31.85% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Cytosorbents	-31.85%	-235.57%	-37.88%

In the previous week, SurgePays had 2 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat SurgePays' score of 1.29 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Cytosorbents	Very Positive

SurgePays has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Summary

Cytosorbents beats SurgePays on 10 of the 15 factors compared between the two stocks.

How does SurgePays compare to Predictive Oncology?

SurgePays (NASDAQ:SURG) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

In the previous week, SurgePays had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for Predictive Oncology. SurgePays' average media sentiment score of 1.29 beat Predictive Oncology's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Positive
Predictive Oncology	Neutral

SurgePays presently has a consensus target price of $3.50, suggesting a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher possible upside, equities analysts plainly believe SurgePays is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has lower revenue, but higher earnings than SurgePays. Predictive Oncology is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
Predictive Oncology	$1.66M	13.78	-$12.66M	-$13.50	N/A

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SurgePays has a net margin of -64.91% compared to Predictive Oncology's net margin of -5,065.23%. SurgePays' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

SurgePays has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Summary

SurgePays beats Predictive Oncology on 11 of the 16 factors compared between the two stocks.

How does SurgePays compare to Modular Medical?

SurgePays (NASDAQ:SURG) and Modular Medical (NASDAQ:MODD) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,017.85%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Modular Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SurgePays has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Modular Medical has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 29.1% of SurgePays shares are owned by company insiders. Comparatively, 7.1% of Modular Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Modular Medical has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Modular Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Modular Medical	N/A	-286.34%	-216.26%

Modular Medical has lower revenue, but higher earnings than SurgePays. Modular Medical is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
Modular Medical	N/A	N/A	-$28.24M	-$14.71	N/A

In the previous week, SurgePays had 2 more articles in the media than Modular Medical. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for Modular Medical. SurgePays' average media sentiment score of 1.29 beat Modular Medical's score of 0.12 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Positive
Modular Medical	Neutral

Summary

SurgePays beats Modular Medical on 11 of the 15 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$8.16M	$18.20B	$38.28B	$12.43B
Dividend Yield	N/A	1.66%	3.14%	8.84%
P/E Ratio	-0.16	68.49	168.79	23.89
Price / Sales	0.14	35.37	596.84	92.04
Price / Cash	N/A	81.53	44.79	60.07
Price / Book	-0.47	6.66	9.29	6.18
Net Income	-$36.07M	$385.08M	$1.07B	$331.73M
7 Day Performance	-6.45%	-2.42%	-2.64%	-2.29%
1 Month Performance	-28.84%	5.19%	-2.27%	-1.62%
1 Year Performance	-89.35%	-14.31%	135.68%	16.81%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	4.319 of 5 stars	$0.31 -3.7%	$3.50 +1,017.9%	-89.0%	$8.16M	$56.96M	N/A	40	News Coverage Positive News Gap Down
PSTV Plus Therapeutics	2.7126 of 5 stars	$4.37 +4.9%	$56.40 +1,189.7%	-51.9%	$30.37M	$5.21M	N/A	20
PETV PetVivo	N/A	$0.80 +5.3%	N/A	-0.5%	$30.08M	$1.05M	N/A	20	Gap Up
CTSO Cytosorbents	3.5446 of 5 stars	$0.39 +2.6%	$5.38 +1,278.2%	-64.5%	$24.51M	$37.20M	N/A	220	Positive News Gap Down
POAI Predictive Oncology	N/A	$7.01 -4.8%	N/A	-40.7%	$23.79M	$1.66M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors

SURG vs. PSTV, PETV, CTSO, POAI, and MODD

How does SurgePays compare to Plus Therapeutics?

Summary

How does SurgePays compare to PetVivo?

Summary

How does SurgePays compare to Cytosorbents?

Summary

How does SurgePays compare to Predictive Oncology?

Summary

How does SurgePays compare to Modular Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SurgePays (SURG) Competitors

SURG vs. PSTV, PETV, CTSO, POAI, and MODD

How does SurgePays compare to Plus Therapeutics?

Does the media refer more to PSTV or SURG?

Do institutionals & insiders hold more shares of PSTV or SURG?

Which has preferable earnings & valuation, PSTV or SURG?

Which has more volatility & risk, PSTV or SURG?

Do analysts recommend PSTV or SURG?

Is PSTV or SURG more profitable?

Summary

How does SurgePays compare to PetVivo?

Do institutionals and insiders have more ownership in SURG or PETV?

Which has stronger valuation and earnings, SURG or PETV?

Does the media refer more to SURG or PETV?

Which has more volatility & risk, SURG or PETV?

Is SURG or PETV more profitable?

Do analysts rate SURG or PETV?

Summary

How does SurgePays compare to Cytosorbents?

Which has stronger earnings & valuation, SURG or CTSO?

Do institutionals and insiders have more ownership in SURG or CTSO?

Do analysts recommend SURG or CTSO?

Is SURG or CTSO more profitable?

Does the media favor SURG or CTSO?

Which has more risk & volatility, SURG or CTSO?

Summary

How does SurgePays compare to Predictive Oncology?

Does the media favor SURG or POAI?

Do analysts prefer SURG or POAI?

Which has higher earnings & valuation, SURG or POAI?

Do insiders and institutionals have more ownership in SURG or POAI?

Is SURG or POAI more profitable?

Which has more volatility and risk, SURG or POAI?

Summary

How does SurgePays compare to Modular Medical?

Do analysts recommend SURG or MODD?

Which has more volatility and risk, SURG or MODD?

Do insiders & institutionals have more ownership in SURG or MODD?

Is SURG or MODD more profitable?

Which has higher valuation and earnings, SURG or MODD?

Does the media favor SURG or MODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools